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Editor ia l  
In this issue of the journal, Ishikawa et al attempt o assess the effects of 2 
different pravastatin dosing regimens in a subgroup of patients with diabetes 
mellitus (DM) in the PravastaUn Anti-atherosclerosis Trial in the Elderly. The 
study is particularly interesting as it focuses on elderly Japanese subjects with 
DM, and these data do provide some insight into the therapeutic effects of 
pravastatin in this particular population. 
Available data from the Scandinavian Simvastatin Survival Study (4S) 1 and 
the Cholesterol and Recurrent Events (CARE) 2 trial have shown the clinical 
benefits of treating hypercholesterolemia to prevent recurrent events in pa- 
tients with DM and a history of coronary disease. A meta-analysis of 8 studies 
assessing lipid-lowering therapy for secondary prevention in patients with DM 
showed a decreased risk for cardiovascular events in treated patients (risk 
reduction, 0.76; 95% CI, 0.59-0.93). 3 Data also exist for primary prevention in 
patients with DM. The Heart Protection Study 4 provided data on almost 3000 
patients who had DM and no history of cardiovascular disease and showed a 
33% reduction in vascular events in this group. 
All of these studies confirmed the link between serum lipid levels and coro- 
nary disease risk in patients with and without DM. Further studies that have 
focused on Japanese patients have confirmed these findings in this population. 
The Japan Lipid Intervention Trial (J-LIT) s found that in Japanese patients aged 
>65 years (mean age, 67.1 years) as well as in those aged <65 years (mean age, 
54.9 years), there was an increase of 1.7% in the relative risk for major coronary 
events for each 1-mg/dL increase in low-density lipoprotein cholesterol level. 
This trial also confirmed the efficacy and tolerability of simvastatin therapy in 
elderly Japanese patients. 
The post hoc analysis presented here has several unique aspects. The focus, 
elderly Japanese patients with DM, addressed a different population from 
the trials noted above. This is important for several reasons. While the Prava- 
statin in Elderly Individuals at Risk of Vascular Disease (PROSPER) trial 6 
specifically evaluated older patients (aged 70-84 years) and found that prava- 
statin significantly lowered the risk for coronary death and nonfatal myocardial 
infarction, the population studied was different. Determining whether prava- 
statin has similar effects in Japanese patients is important, as Japanese subjects 
may have significant differences in lipid metabolism than Anglo-European 
subjects. Data from Japan have suggested that in nonobese patients with DM, 
both visceral and subcutaneous fat accumulation are correlated with insulin 
resistance, whereas only visceral fat accumulation is linked with elevated tri- 
glyceride (TG) levels. ~ Many patients with DM have elevated TG levels, and the 
choice of a hydroxymethyiglutaryi co-enzyme A reductase inhibitor in these 
patients hould take this into consideration. The J-LIT S study also demonstrat- 
ed that the risk for major coronary events increased as TG level increased. 
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Whether  or not lowering TG levels is more important in this group is not clear 
but certainly should be considered. As both atorvastatin and rosuvastatin are 
more effective in lowering TG levels, they may be better choices for patients with 
DM, unless these patients are concomitantly treated with fibrates for optimal TG 
reduction.S,9 
The authors do a nice job of identifying and discussing the limitations of this 
study. While institutional review board approval and written in[ormed consent 
were not obtained, the authors point out that this was not required in Japan 
at the t ime of study enrollment. Despite the limitations of this analysis, it is 
encouraging to see data from non-Anglo-European populations being submit- 
ted for publication. Generating population-specific data remains an important 
and often overlooked aspect of clinical trial design. It is exciting to see that the 
well-appreciated benefits o[ statin therapy appear  to be just as striking in this 
population of elderly Japanese patients with DM as they have proved to be in 
American and European populations. 
Judd L. Walson, MD, MPH 
Editor-in-Chief 
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